Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vividion Therapeutics to Present Data on Novel Covalent E3 Ligase Engager Supporting Broad Targeted Protein Degradation at 2020 AACR Meeting","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Logos Capital","pharmaFlowCategory":"D","amount":"$135.0 million","upfrontCash":"Undisclosed","newsHeadline":"Vividion Announces $135 Million Series C Financing to Fuel Broad Pipeline\nof Precision Oncology and Immunology Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"February 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$135.0 million","newsHeadline":"Vividion Therapeutics Earns First Milestone Payment for Advancement of Program Addressing High Value Oncology Target","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","amount":"$2,000.0 million","upfrontCash":"$1,500.0 million","newsHeadline":"Bayer Strengthens Drug Discovery Platform Through Acquisition of Vividion Therapeutics","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Tavros Therapeutics","pharmaFlowCategory":"D","amount":"$448.0 million","upfrontCash":"$17.5 million","newsHeadline":"Tavros Therapeutics and Vividion Therapeutics Announce Strategic Collaboration to Discover and Enhance Targeted Oncology Programs","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Small molecule","productStatus":"Undisclosed","date":"October 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vividion Therapeutics Starts Phase I Clinical Trial in Advanced Solid Tumors with KEAP1 Activator","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Vividion Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Vividion Therapeutics Starts Phase I Clinical Trial in Advanced Solid and Hematologic Tumors with Oral STAT3 Inhibitor","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"}]

    Find Clinical Drug Pipeline Developments & Deals by Vividion Therapeutics

    Menu

    Vividion Therapeutics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Vividion Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vividion Therapeutics Starts Phase I Clinical Trial in Advanced Solid and Hematologic Tumors with Oral STAT3 Inhibitor

              Details:

              VVD-130850 is an investigational oral small molecule inhibitor of STAT3 transcription factor. It is being evaluated in phase 1 clinical trials in combination with pembrolizumab for the treatment of advanced solid tumors & advanced hematologic tumors.

              Lead Product(s): VVD-130850,Pembrolizumab

              Therapeutic Area: Oncology Product Name: VVD-130850

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 06, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Vividion Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vividion Therapeutics Starts Phase I Clinical Trial in Advanced Solid Tumors with KEAP1 Activator

              Details:

              VVD-130037 is the investigational oral Kelch-like ECH Associated Protein 1 (KEAP1) activator, which is investigated for the treatment of advanced solid tumors.

              Lead Product(s): VVD-130037

              Therapeutic Area: Oncology Product Name: VVD-130037

              Highest Development Status: Phase I Product Type: Small molecule

              Partner/Sponsor/Collaborator: Bayer AG

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 18, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Vividion Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Tavros Therapeutics and Vividion Therapeutics Announce Strategic Collaboration to Discover and Enhance Targeted Oncology Programs

              Details:

              Tavros leverages its functional and computational genomics technologies to uncover unique vulnerabilities within tumors to discover novel targets and biomarkers in areas of high unmet clinical need and identify novel clinical positioning strategies for existing molecules.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Recipient: Tavros Therapeutics

              Deal Size: $448.0 million Upfront Cash: $17.5 million

              Deal Type: Collaboration October 12, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Vividion Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Bayer Strengthens Drug Discovery Platform Through Acquisition of Vividion Therapeutics

              Details:

              Following closing of the acquisition, Bayer will own full rights to Vividion’s proprietary discovery platform, which comprises three integrated, synergistic components: a novel chemoproteomic screening technology, an integrated data portal, and a proprietary chemistry library.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Bayer AG

              Deal Size: $2,000.0 million Upfront Cash: $1,500.0 million

              Deal Type: Acquisition August 05, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Vividion Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vividion Therapeutics Earns First Milestone Payment for Advancement of Program Addressing High Value Oncology Target

              Details:

              The payment follows Vividion’s completion of a preclinical data package for a program addressing a well-known, but difficult to drug target, for the potential treatment of oncology indications.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

              Deal Size: Undisclosed Upfront Cash: $135.0 million

              Deal Type: Collaboration June 24, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Vividion Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vividion Announces $135 Million Series C Financing to Fuel Broad Pipeline of Precision Oncology and Immunology Programs

              Details:

              Vividion’s initial wave of wholly owned assets includes programs targeting the KEAP1-NRF2 axis, with antagonists for the treatment of NRF2 mutant and NRF2 addicted cancers, as well as agonists for the treatment of inflammatory diseases.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Logos Capital

              Deal Size: $135.0 million Upfront Cash: Undisclosed

              Deal Type: Series C Financing February 24, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Vividion Therapeutics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Vividion Therapeutics to Present Data on Novel Covalent E3 Ligase Engager Supporting Broad Targeted Protein Degradation at 2020 AACR Meeting

              Details:

              First reported E3 ligase beyond Cereblon and VHL shown to support broad targeted protein degradation of multiple targets in vivo.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 15, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY